Animation - Targeted Therapy in NSCLC
Slide Show - Targeted Therapy in NSCLC
1.
What is targeted therapy for lung cancer?
2.
What targeted therapies are used for people with the EGFR mutation?
3.
What targeted therapies are used for people with the ALK mutation?
4.
What targeted therapies are used for people with the ROS1 mutation?
5.
What is the importance of combination therapies for BRAF?
6.
What is the future of combination therapy for lung cancer?
7.
Can biomarker testing help identify clinical trial opportunities for me?
8.
How can communities of color increase their participation in clinical trials?
9.
What targeted treatments are used for non-small cell lung cancer (NSCLC)?
Expert Video - What targeted treatments are used for non-small cell lung cancer (NSCLC)?
Medical oncologist Dr. Manish Patel provides an overview of targeted treatments for non-small cell lung cancer (NSCLC). Targeted therapy is a cancer treatment directed towards specific mutations that drive cancer to grow and spread. Targeted therapies interrupt the growth and function of cancer cells while avoiding healthy cells. So there can be fewer side effects than with standard chemotherapy. He discusses the example of targeted therapy that specifically targets a mutation in NSCLC called EGFR. About 30 to 40% of patients with NSCLC will have a targeted therapy that can be used to treat their cancer.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
Section: Targeted Therapy in NSCLC
Expert Videos
Animation - Targeted Therapy in NSCLC
Slide Show - Targeted Therapy in NSCLC
1.
What is targeted therapy for lung cancer?
2.
What targeted therapies are used for people with the EGFR mutation?
3.
What targeted therapies are used for people with the ALK mutation?
4.
What targeted therapies are used for people with the ROS1 mutation?
5.
What is the importance of combination therapies for BRAF?
6.
What is the future of combination therapy for lung cancer?
7.
Can biomarker testing help identify clinical trial opportunities for me?
8.
How can communities of color increase their participation in clinical trials?
9.
What targeted treatments are used for non-small cell lung cancer (NSCLC)?
